What’s Behind the 140% Surge in Radiopharm Theranostics Stock?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
Source: Benzinga
Stock Performance: Radiopharm Theranostics Limited (NASDAQ: RADX) saw its stock rise 141.31% to $10.27 on Monday, with a trading volume significantly higher than its average.
Clinical Trial Results: The company shared promising interim data from its Phase 2b trial of RAD 101, showing that 92% of patients achieved concordance with MRI in detecting brain metastases.
Market Potential: RAD 101 is projected to have a U.S. market opportunity exceeding $500 million annually, with the company aiming to initiate a pivotal study by the end of 2026.
Regulatory Milestones: RAD 101 has received FDA Fast Track Designation, and the company has also secured approval for a Phase 1 trial of RAD 402 for treating advanced prostate cancer.
Analyst Views on RADX
Wall Street analysts forecast RADX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RADX is 20.33 USD with a low forecast of 15.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.050
Low
15.00
Averages
20.33
High
30.00
Current: 5.050
Low
15.00
Averages
20.33
High
30.00
About RADX
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
